Healthcare >> CEO Interviews >> July 13, 2009
PHILLIP CHAN, MD led healthcare life science investments as Partner for NJTC
Venture Fund prior to joining CytoSorbents. He is responsible for numerous
investments in the therapeutics, medical device and diagnostics space and
actively managed them at the Board level. Dr. Chan co-founded Andrew
Technologies, a medical device company developing novel surgical instruments for
plastic surgery and continues as a Board Director. Dr. Chan is a Board-certified
internal medicine physician with a strong background in clinical medicine and
research, having completed his residency at Harvard Medical School at the Beth
Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale
University School of Medicine and his BS in cell and molecular biology from Co Profile
Dr. Chan: MedaSorb Technologies Corporation is a publicly traded medical device
company, ticker symbol MSBT, that is focused on treating human diseases
